BioCentury
ARTICLE | Emerging Company Profile

Stabilizing damaged goods

How Methuselah is patching up damaged proteins to treat aging-related diseases

March 15, 2018 6:50 PM UTC

Methuselah Health Inc. aims to treat aging-related diseases by stabilizing proteins that have adopted dysfunctional conformations as a result of genomic or environmental damage. By studying damaged proteins instead of DNA, the newco can find disease-driving targets that genomics studies miss.

“We started Methuselah in response to the realization that genome-wide association studies (GWAS) were not going to be the answer to target identification for the bulk of common degenerative diseases of middle and old age,” CEO and Medicxi co-founder and Partner David Grainger told BioCentury. “The core of the Methuselah hypothesis is that it’s proteome instability, rather than DNA-encoded loss of function” that causes late-onset diseases like Type II diabetes, Alzheimer’s disease and osteoarthritis...

BCIQ Company Profiles

Methuselah Health Inc.